A New Era in Viral Treatment Begins Here
First-in-class therapies targeting the core mechanisms of Viral replication.
A New Era in Viral Treatment Begins Here
First-in-class therapies targeting the core mechanisms of Viral replication.
About CureViva Therapeutics
Our Mission
- At CureViva Therapeutics is a biotechnology startup originating from Yale University, focused on developing first-in-class small molecule therapies for RNA viruses.
- With a strong foundation in molecular biology, virology, and translational science, we are committed to transforming viral therapy by addressing unmet clinical needs and drug resistance challenges.
CureViva Science &Technology
Why novel mechanism
Why novel mechanism
Why novel mechanism
Current HIV therapies target viral enzymes or entry pathways, but none address HIV's nuclear RNA export mechanism.
Our Expertise
Why novel mechanism
Why novel mechanism
- Our team of scientists and researchers are leaders in the field of biotechnology. We have extensive experience in developing and commercializing cutting-edge biotech products and HIV therapies, and we are constantly exploring new ways to improve patient outcomes.
Our Innovation
Why novel mechanism
Our Innovation
We use a high-throughput, cell-free system to identify inhibitors
- First-in-class mechanism
- Potential for broad use in resistant patients
- High synergy with existing ART
Welcome to CureViva Therapeutics
At Curviva Therapeutics, we are pioneering a novel class of HIV therapeutics by targeting a critical mechanism untouched by existing treatments.